Business
The ICR, Sareum and CRT Limit
The ICR, Sareum and CRT Limit.
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n RNS Number : 8141F Sareum Holdings PLC 20 January 2010 \n \n\n\n\n\n(AIM: SAR)\n\n\n20 January 2010\n\n\n\n\n\nSAREUM HOLDINGS PLC (\"Sareum\")\nTHE INSTITUTE OF CANCER RESEARCH, SAREUM AND CANCER RESEARCH TECHNOLOGY LIMITED \nNew Molecules Increase the Effectiveness of Certain Cancer Therapies \nScientists at The Institute of Cancer Research (\"ICR\") and Sareum have developed novel chemical compounds that increase the effectiveness of current cancer therapeutics, an example of which is published in the latest edition of the journal Molecular Cancer Therapeutics*. \nThese compounds originate from the Checkpoint Kinase 1 (\"CHK1\") Inhibitor joint research collaboration between the ICR, Sareum and Cancer Research Technologies Limited (\"CRT\"). \nCHK1 is a key component of a biochemical pathway responsible for reducing the effectiveness of traditional cancer therapeutics such as chemotherapy. The collaboration has developed novel, potent and selective CHK1 inhibitors that, in combination with cancer chemotherapeutics gemcitabine (Gemzar) or irinotecan (Campto), significantly reduce tumour growth in preclinical models when compared to the chemotherapeutic alone.\nThe ICR, Sareum and CRT are encouraged that the significant recent progress made by the collaboration has been published in a peer-reviewed scientific journal and believe this will assist in discussions with potential licensing partners.\n * Walton, M.I. et al, \"The Preclinical Pharmacology and Therapeutic Activity of the Novel CHK1 Inhibitor SAR-020106. Mol. Cancer Ther. (2010), 9(1), 89-100.\nProfessor Paul Workman, Director of The Cancer Research UK Centre for Cancer Therapeutics at the ICR, said: \"These are very exciting times in cancer drug development. This collaboration has brought together expertise and experience at the ICR and Sareum in the discovery of molecularly targeted anticancer agents, and has effectively demonstrated the potential to use existing drugs more effectively and hence improve cancer management.\"\nSareum's CEO, Dr Tim Mitchell, said: \"This publication...